4. Kellerer M, Kaltoft MS, Lawson J, et al. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial.Diabetes Obes Metab. 2022;24(9):1788-1799. doi:10.1111/dom.14765 5. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.N Engl J Med. 1988;318(19):1231-1239. doi:10.1056/ NEJM198805123181903 6. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes.Diabetes. 2004;53(suppl 3):S16-S21. doi:10.2337/diabetes.53.suppl_3.S16 7. Rosenstock J, Wysham C, Fr√≠as JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.Lancet. 2021;398(10295):143-155. doi:10.1016/ S0140-6736(21)01324-6 